Lanopepden mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598306

CAS#: 1441390-17-5 (mesylate)

Description: Lanopepden mesylate has been used in trials studying the treatment of Pneumonia, Infections, Bacterial, Skin Diseases, Infectious, and Skin Infections, Bacterial.

Price and Availability




Lanopepden mesylate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 598306
Name: Lanopepden mesylate
CAS#: 1441390-17-5 (mesylate)
Chemical Formula: C23H38FN7O7S
Exact Mass:
Molecular Weight: 575.6574
Elemental Analysis: C, 47.99; H, 6.65; F, 3.30; N, 17.03; O, 19.45; S, 5.57

Related CAS #: 1441390-17-5 (mesylate)   1152107-25-9 (free base)    

Synonym: Lanopepden mesylate; GSK1322322 mesylate salt; GSK 1322322 mesylate salt GSK-1322322 mesylate salt;

IUPAC/Chemical Name: N-((R)-2-(cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazinyl)-3-oxopropyl)-N-hydroxyformamide methanesulfonic acid


InChi Code: InChI=1S/C23H36FN7O6S/c1-16-25-21(20(24)22(26-16)30-8-7-29-9-10-36-14-19(29)13-30)27-28-23(33)18(11-17-5-3-4-6-17)12-31(15-32)37-38(2,34)35/h15,17-19H,3-14H2,1-2H3,(H,28,33)(H,25,26,27)/t18-,19+/m1/s1

SMILES Code: O=CN(C[C@@H](CC1CCCC1)C(NNC2=NC(C)=NC(N3C[C@@]4([H])COCCN4CC3)=C2F)=O)O.CS(=O)(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Seo JH, Park JB, Choi WK, Park S, Sung YJ, Oh E, Bae SK. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate. Drug Des Devel Ther. 2015 Jul 30;9:3961-8. doi: 10.2147/DDDT.S87687. eCollection 2015. PubMed PMID: 26251575; PubMed Central PMCID: PMC4524531.

2: Carris N, Kutner S, Reilly-Rogers S. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate. Ann Pharmacother. 2014 Oct;48(10):1343-9. doi: 10.1177/1060028014543099. Epub 2014 Jul 15. Review. PubMed PMID: 25028744.

3: Sakellariou GK, Pearson T, Lightfoot AP, Nye GA, Wells N, Giakoumaki II, Griffiths RD, McArdle A, Jackson MJ. Long-term administration of the mitochondria-targeted antioxidant mitoquinone mesylate fails to attenuate age-related oxidative damage or rescue the loss of muscle mass and function associated with aging of skeletal muscle. FASEB J. 2016 Nov;30(11):3771-3785. Epub 2016 Aug 22. PubMed PMID: 27550965; PubMed Central PMCID: PMC5067250.

4: Yokoo M, Kubota Y, Tabe Y, Kimura S. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511. Biol Pharm Bull. 2015;38(3):411-6. doi: 10.1248/bpb.b14-00652. Epub 2015 Jan 8. PubMed PMID: 25757922.

5: de Paula K, Camí GE, Brusau EV, Narda GE, Ellena J. Mebendazole mesylate monohydrate: a new route to improve the solubility of mebendazole polymorphs. J Pharm Sci. 2013 Oct;102(10):3528-38. doi: 10.1002/jps.23658. Epub 2013 Jul 29. PubMed PMID: 23897162.

6: Jain S, Vahdat LT. Eribulin mesylate. Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. Review. PubMed PMID: 21859830.

7: Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P. Eribulin mesylate. Nat Rev Drug Discov. 2011 Mar;10(3):173-4. doi: 10.1038/nrd3389. PubMed PMID: 21358731.

8: Baldini E, Sorrenti S, D'Armiento E, Guaitoli E, Morrone S, D'Andrea V, Gnessi L, Moretti C, Antonelli A, Catania A, De Antoni E, Ulisse S. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. Clin Ter. 2012;163(5):e307-13. PubMed PMID: 23099978.

9: Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427. PubMed PMID: 21937277.

10: Greco K, Bogner R. Solution-mediated phase transformation of haloperidol mesylate in the presence of sodium lauryl sulfate. AAPS PharmSciTech. 2011 Sep;12(3):909-16. doi: 10.1208/s12249-011-9656-4. Epub 2011 Jul 6. PubMed PMID: 21732157; PubMed Central PMCID: PMC3167271.

11: Genina N, Janßen EM, Breitenbach A, Breitkreutz J, Sandler N. Evaluation of different substrates for inkjet printing of rasagiline mesylate. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1075-83. doi: 10.1016/j.ejpb.2013.03.017. Epub 2013 Apr 4. PubMed PMID: 23563101.

12: Cristina Castelli M, Bhaskar S, Lippman J. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. Clin Ther. 2013 Jun;35(6):862-9. doi: 10.1016/j.clinthera.2013.05.001. PubMed PMID: 23795577.

13: Eribulin mesylate (Halaven) for breast cancer. Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1. PubMed PMID: 21502935.

14: Reddy PS, Babu KS, Kumar N. A validated normal phase LC method for enantiomeric separation of rasagiline mesylate and its (S)-enantiomer on cellulose derivative-based chiral stationary phase. Chirality. 2013 Jun;25(6):324-7. doi: 10.1002/chir.22150. Epub 2013 May 9. PubMed PMID: 23658136.

15: Nacsa ED, Lambert TH. Cyclopropenone catalyzed substitution of alcohols with mesylate ion. Org Lett. 2013 Jan 4;15(1):38-41. doi: 10.1021/ol302970c. Epub 2012 Dec 13. PubMed PMID: 23237617.

16: Li Q, Liu D, Huang X, Guo L. Fasudil mesylate protects PC12 cells from oxidative stress injury via the Bax-mediated pathway. Cell Mol Neurobiol. 2011 Mar;31(2):243-50. doi: 10.1007/s10571-010-9614-9. PubMed PMID: 21061151.

17: Yoshida S, Karaki F, Uchida K, Hosoya T. Generation of cycloheptynes and cyclooctynes via a sulfoxide-magnesium exchange reaction of readily synthesized 2-sulfinylcycloalkenyl triflates. Chem Commun (Camb). 2015 May 25;51(42):8745-8. doi: 10.1039/c5cc01784j. PubMed PMID: 25882340.

18: Li Q, Chen Y, Sun L, Fu G, Guo L. Vasodilatation produced by fasudil mesylate in vivo and in vitro. Vascul Pharmacol. 2011 Nov-Dec;55(5-6):121-6. doi: 10.1016/j.vph.2011.06.005. Epub 2011 Jul 6. PubMed PMID: 21763460.

19: Zou N, Chen R, Qin Y, Song S, Tang X, Pan C. Comparison of pulse glow discharge-ion mobility spectrometry and liquid chromatography with tandem mass spectrometry based on multiplug filtration cleanup for the analysis of tricaine mesylate residues in fish and water. J Sep Sci. 2016 Sep;39(18):3638-46. doi: 10.1002/jssc.201600614. Epub 2016 Aug 25. PubMed PMID: 27440123.

20: Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA, Slusher BS. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res. 2011 Jun 1;71(11):3952-62. doi: 10.1158/0008-5472.CAN-10-4184. Epub 2011 Apr 15. PubMed PMID: 21498637.